Skip to content

GynART

Active Private limited companyfounded 2007active for 19 yearsLindelei 38, 2630 AartselaarKBO/BCE: BE 0892.229.457

Lifetime

18 annual accounts with figures on one time axis
peak of €687,160 in 2008
€390,107▲ 70.4%
lowest -€104,017 in 2009
€250,795▲ 76.4%
peak of €537,127 in 2025
€537,127▲ 19.9%
€311,639▲ 6.7%
Board5 names since 2015
5 directors and 4 others
Documentsfilings and deeds
18-08-202618 days late
2025abbreviated format
Gross margin from €228,916 to €390,107Result from €142,175 to €250,795Dividend €161,653Equity from €447,985 to €537,127Investments €90,905

Key points

from the 2025 annual accounts

Equity

€537,127 ▲ 19.9%
447,9852024+250,795Profit-161,653Dividend537,1272025

GynART paid out €161,653 in dividends. That is 64% of the 2025 profit.

Result

€250,795 ▲ 76.4%
€142,0002024€251,0002025

The result rose in 2025: different schema filed.

Investments

€90,905 4.1 times depreciation
2021202220232025

Green is investment, beige is depreciation. Machinery stands 512.3% higher than in 2024.

2025 accounts filed 18 days after the deadline

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 17,816 companies had the same profile as GynART has now. Each dot stands for 45 companies, two years later.

96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
  • Small
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 17,816 companies, not a prediction for GynART. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 01-07-2015
Manager, since 01-07-2015
Manager, since 01-07-2015
Director
Manager
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0892229457
Company renamed from DR MARC COPPENS - DR to GynART (director) and (director) resign · (director) and (director) reappointed · “De uitoefening van de geneeskunde met specialisatie gynaecologie-verloskunde door de arts-aandeelhouder, met…” (deed in Dutch) · General meeting of 03-01-2023 · Gazette deed
(manager) and (manager) reappointed General meeting of 28-10-2017 · Gazette deed
appointed as manager General meeting of 09-06-2015 · Gazette deed
All 31 events

Comparable companies

same main activity, similar in size and age
Company
GynART Aartselaar €848,766 €390,107 63.3% -
Dr. S. Platteaux & Dr. G. Huysmans Puurs-Sint-Amands €782,488 €359,152 74.9% -
DR. K. VAN HOUDENHOVEN Bonheiden €987,419 €393,555 94.6% -
Dr. A. Borms Schilde €920,350 €428,037 54.2% -
MEDI-NOUR Wemmel €803,762 €370,567 85.0% -
DOKTER ANNE STRUELENS Hasselt €883,210 €375,659 90.7% -
DR. DE CUYPER EVA Genk €819,409 €390,356 82.9% -

These companies have the same main activity as GynART: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €782,000 and €987,000, founded between 2005 and 2010.

Official details

Source: KBO
Status
Active since 21-09-2007Normal situation
Activity
Specialist medical practiceNACE 86220and 1 other
Establishment unit
2.258.868.2962630 Aartselaar, since 21-09-2007
Financial year end
31 December
Peppol
Reachable since 16-12-2025
Company details

Annual accounts 2025

≈ €590,000estimated
€848,766▲ 14.7%
Filing
Filed on 18-08-2026
Financials

Insights on GynART

GynART files the abbreviated format. That format states no turnover. The gross margin fell from €687,160 in 2008 to €390,107 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about GynART

What is the company number of GynART?
The company number of GynART is 0892.229.457. The VAT number is the same number with BE in front: BE 0892.229.457.
Where is GynART based?
The registered office is at Lindelei 38, 2630 Aartselaar.Company details
What does GynART do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of GynART?
GynART is a private limited company (BV).
When was GynART founded?
GynART was founded on 21-09-2007.
Is GynART still active?
Yes, GynART is an active enterprise in the KBO register.
What is the turnover of GynART?
The turnover in financial year 2025 is ≈ €590,000. This figure is estimated from the gross margin of €390,107 and 31 comparable companies (NACE 86220). It probably lies between €520,000 and €820,000.Financials
Is GynART profitable?
In financial year 2025, GynART made a profit of €250,795.
Where can I find the annual accounts of GynART?
GynART filed 18 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of GynART due?
GynART must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.